Neurocrine Biosciences Q2 Adj EPS $1.25 Beats $0.77 Estimate, Sales $452.70M Beat $448.89M Estimate
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences reported Q2 adjusted earnings of $1.25 per share, beating the analyst consensus estimate of $0.77 by 62.34%. The company also reported quarterly sales of $452.70 million, surpassing the analyst consensus estimate of $448.89 million by 0.85%. Both earnings and sales have increased compared to the same period last year.
August 01, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Neurocrine Biosciences reported Q2 earnings and sales that beat analyst estimates. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100